New Retina Radio by Eyetube

Retina Today
  • 4.4 (18)
  • Science
  • Updated Weekly

New Retina Radio is a place to hear stories about retina that are told nowhere else.

  1. 3d ago

    The Fellow Eye: Episode 7

    Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Matthew Starr, MD, a vitreoretinal surgeon at the Mayo Clinic, and Timothy Xu, MD, a retina fellow at Wills Eye Hospital, to discuss retained lens fragments and secondary IOLs. They share complex cases, when to consider following patients medically, surgical techniques for removing fragments, and how to make the best secondary lens choice.

    The Fellow Eye: Episode 7

  2. Sep 24

    Spotlight on UNITY® VCS: 50 Cases In

    In this episode of RetinaLive focused on UNITY® VCS|CS, Matt Cunningham, MD, FASRS, welcomes Steven Yeh, MD, FASRS for a reflection on early clinical experience with the UNITY® VCS system following the first 50 cases. The discussion highlights real-world insights on surgical efficiency, fluidics stability, and intraoperative control across a range of case complexities. From seamless OR integration to advancements in 27-gauge instrumentation and laser delivery, the conversation offers practical perspectives on adoption, training, and how evolving technology can enhance surgeon confidence and patient care. For Important Product Information, visit unityvcs.com. Speakers are paid Alcon consultants. The views expressed are their own. Disclaimers: 3:58: For posterior segment surgeries/posterior cassette pack § ~1.7 minutes faster. 4:30: For posterior segment surgeries/posterior cassette pack § ~1.7 minutes faster. 10:49: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:09: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:17: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:46: Versus Alcon's Non-Dynamic Stiffener 27+ technology 11:58: MSLP(4) is 3 times faster than SSLP 12:15: MSLP(4) is 3 times faster than SSLP 12:26: MSLP(4) is 3 times faster than SSLP 13:18: Versus Alcon's Non-Dynamic Stiffener 27+ technology 13:39: Versus Alcon's Non-Dynamic Stiffener 27+ technology 17:30: Versus Alcon's Non-Dynamic Stiffener 27+ technology 18:25: For posterior segment surgeries/posterior cassette pack ~1.7 minutes faster. References: 1. Alcon Data on File, 2025. (REF-28170) 2. UNITY™ VCS and CS User Manual 3. Vasavada V, Agrawal D, Vasavada SA, Vasavada AR, Yagnik J. Intraoperative performance and early postoperative outcomes following phacoemulsification with three fluidic systems: A randomized trial. J Refract Surg. 2024;40(5):e304-e312. 4. Sugiura Y, Okamoto F, Okamoto Y, Hiraoka T, Oshika T. Intraocular pressure fluctuations during microincision vitrectomy with Constellation Vision System. Am J Ophthalmol. 2013;156(5)941-947 5. Alcon data on file 2024. (REF-24576) 6. Alcon data on file 2024 (REF-24615) 7. Alcon data on file 2024 (REF-24379) 9. Alcon data on file 2024 (REF-24644) 10. Alcon data on file 2024. (REF-24615) 11. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use. Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600114

  3. Sep 18

    Vitreous Hemorrhage Following PVD: Who Needs Surgery?

    How aggressively should you manage a vitreous hemorrhage after a PVD when you can't see the retina underneath it? Barton Blackorby, MD, moderates a discussion with Matt Starr, MD, and Kyle Kovacs, MD, about a study published in Ophthalmology by Hasbolat et al examining 366 patients with PVD-related vitreous hemorrhage initially managed with observation. The panel discusses how exam technique and B-scan reliance may affect detachment detection rates, debates follow-up intervals given that most retinal detachments in the study occurred within the first 3 weeks, and shares their own thresholds for moving to early vitrectomy versus continued observation, including how they counsel patients eager for faster visual recovery.

    Vitreous Hemorrhage Following PVD: Who Needs Surgery?

  4. Sep 10

    Spotlight on UNITY® VCS: Breaking New Ground

    In this episode of RetinaLive focused on UNITY® VCS|CS, Jay Sridhar, MD is joined by Nina Berrocal, MD for a forward-looking discussion on adopting next-generation surgical technology. The conversation explores how UNITY® VCS is enabling innovation in a new retina practice setting, with a focus on fluidics stability, integrated anterior and posterior segment capabilities, and enhanced intraoperative efficiency. Through real-world perspectives, the episode highlights the role of advanced technology in simplifying surgical workflows, and supporting the training of the next generation of retina surgeons. For Important Product Information, visit unityvcs.com. Speakers are paid Alcon consultants. The views expressed are their own. Disclaimers: 4:05: Based on Bench Data. UNITY® VCS with HYPERVIT® 30k cpm vitrectomy probe vs. CONSTELLATION® VS with HYPERVIT® 20k cpm vitrectomy probe 6:13: *Mean fluctuation at flow vs. setpoint of 2.36 ± 2.13, 4.19 ± 1.97, 1.84 ± 2.82, and 2.13 ± 2.86 mmHg during phacoemulsification, irrigation/aspiration (IA), vitrectomy, and extrusion/fragmentation, respectively. IOP setpoint as low as 16 mmHg (posterior) and 20 mmHg (anterior) without exceeding a mean fluctuation of 4.19 ± 1.97 mmHg 9:08: MSLP(4) is 3 times faster than SSLP References: 1. UNITY™ VCS and CS User Manual Unity Phaco Handpiece Directions for Use.  2. Alcon data on file 2024 (REF-24615) 3. Alcon data on file 2024 (REF-24379) 4. Alcon data on file 2024 (REF-24576) 5. Alcon Data on File (REF-27800) 6. UNITY™ VCS and CS User Manual 7. Alcon data on file 2024. (REF-24899)   Sponsored by Alcon, Inc. © 2026 Alcon Inc. 07/26 US-UVC-2600112

  5. Aug 27

    ASRS '26: ArMaDa/GARDian Results and Real-World YAG Complication Incidence

    Can a single molecule treat both GA and Stargardt Disease? And if so, how far along is the research? Jay Chhablani, MD, joins New Retina Radio to share data from ArMaDa and GARDian, which assessed OCU410 (Ocugen) in geographic atrophy and Stargardt disease, respectively. And Jordan Deaner, MD, sits down to discuss his research on real-world retinal tears and detachments following YAG capsulotomy. What are the actual incidence rates? And what risk factors were identified? Stick with us to find out.

    ASRS '26: ArMaDa/GARDian Results and Real-World YAG Complication Incidence

  6. Aug 20

    Comparing Ocular AEs in Next-Gen Treatments

    What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.

  7. Aug 18

    The Story Behind LYTENAVA™: From FDA Approval to Retina Practice

    In this episode of New Retina Radio, host Barry Kuppermann, MD, PhD, sits down with Bob Jahr, CEO of Outlook Therapeutics, to discuss the FDA approval of LYTENAVA™ (bevacizumab-vikg), the only FDA-approved ophthalmic bevacizumab formulation for nAMD.1,2 They explore the regulatory journey over the course of more than 8 years,3 the rigorous FDA review process,4 manufacturing and product quality, commercialization plans, payer considerations, and future development. Please see the Important Safety Information and full US Prescribing Information for LYTENAVA. Intended for a US audience only. Sponsored by Outlook Therapeutics References 1. Harp MD. FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD. Ophthalmology Times. Published July 24, 2026. Accessed July 28, 2026. https://www.ophthalmologytimes.com/view/fda-approves-outlook-therapeutics-lytenava-for-the-treatment-of-wet-amd 2. LYTENAVA™ (bevacizumab-vikg) prescribing information. Outlook Therapeutics; 2026. 3. Outlook Therapeutics. Oncobiologics changes name to Outlook Therapeutics; announces next steps in executing ONS-5010 clinical and regulatory strategy. Published December 3, 2018. Accessed July 24, 2026. https://ir.outlooktherapeutics.com/news-releases/news-release-details/oncobiologics-changes-name-outlook-therapeutics-announces-next 4. US Food and Drug Administration. The FDA's drug review process: ensuring drugs are safe and effective. Updated January 4, 2018. Accessed July 28, 2026. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective

  8. Aug 13

    The Fellow Eye: Episode 6

    Co-hosts Justin C. Muste, MD, and David Fell, MD, are joined by Monia Reding, MD, a retina fellow at Casey Eye Institute, and Benjamin Young, MD, assistant professor of Ophthalmology at Casey Eye Institute, to talk about lasers. They share the pros and cons of slit-lamp laser and indirect, ergonomics, laser settings, difficult scenarios, and the personal experiences that shape their practice patterns.

    The Fellow Eye: Episode 6
See All (265)

4.4
out of 5
18 Ratings

About

New Retina Radio is a place to hear stories about retina that are told nowhere else.

Information

  • Creator
    Retina Today
  • Years Active
    2016 - 2026
  • Episodes
    265
  • Rating
    Clean
  • Copyright
    © 2024 Bryn Mawr Communications LLC
  • Show Website
    New Retina Radio by Eyetube

You Might Also Like